by Zhao, Yiming, Fay, Francois, Hak, Sjoerd, Perez-Aguilar, Jose Manuel, Sanchez-Gaytan, Brenda L, Goode, Brandon, Duivenvoorden, Raphaël, de Lange Davies, Catharina, Bjørkøy, Astrid, Weinstein, Harel, Fayad, Zahi A, Pérez-Medina, Carlos and Mulder, Willem J M
Abstract:
A major goal of cancer nanotherapy is to use nanoparticles as carriers for targeted delivery of anti-tumour agents. The drug–carrier association after intravenous administration is essential for efficient drug delivery to the tumour. However, …
Reference:
Augmenting drug–carrier compatibility improves tumour nanotherapy efficacy (Zhao, Yiming, Fay, Francois, Hak, Sjoerd, Perez-Aguilar, Jose Manuel, Sanchez-Gaytan, Brenda L, Goode, Brandon, Duivenvoorden, Raphaël, de Lange Davies, Catharina, Bjørkøy, Astrid, Weinstein, Harel, Fayad, Zahi A, Pérez-Medina, Carlos and Mulder, Willem J M), In Nature Communications, volume 7, 2016.
Bibtex Entry:
@article{zhao_augmenting_2016,
	title = {Augmenting drug–carrier compatibility improves tumour nanotherapy efficacy},
	volume = {7},
	url = {http://www.nature.com/doifinder/10.1038/ncomms11221},
	doi = {10.1038/ncomms11221},
	abstract = {A major goal of cancer nanotherapy is to use nanoparticles as carriers for targeted delivery of anti-tumour agents. The drug–carrier association after intravenous administration is essential for efficient drug delivery to the tumour. However, ...},
	language = {English},
	journal = {Nature Communications},
	author = {Zhao, Yiming and Fay, Francois and Hak, Sjoerd and Perez-Aguilar, Jose Manuel and Sanchez-Gaytan, Brenda L and Goode, Brandon and Duivenvoorden, Raphaël and de Lange Davies, Catharina and Bjørkøy, Astrid and Weinstein, Harel and Fayad, Zahi A and Pérez-Medina, Carlos and Mulder, Willem J M},
	year = {2016},
	pmid = {27071376},
	pmcid = {PMC4833858},
	note = {Publisher: Nature Publishing Group},
	pages = {11221}
}